Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects - Wikidata - wikimedia - TriplyDB

Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects

Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects

http://www.wikidata.org/entity/Q28196731

about

sameAs

Antiplatelet resistance in stroke Aspirin resistance: current status and role of tailored therapy Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study Thrombelastography: current clinical applications and its potential role in interventional cardiology.Biochemical aspirin resistance in stroke patients - a cross-sectional single centre study Pharmacogenomics of platelet responsiveness to aspirin.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo Adipokines and thrombosis.Platelet activation in obesity and metabolic syndrome.Overcoming aspirin treatment failure in diabetes.Aspirin responsiveness changes in obese patients following bariatric surgery.Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.Safety of ultrasound-guided transrectal extended prostate biopsy in patients receiving low-dose aspirin.Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.Obesity: is it a major risk for developing aspirin resistance in older adults?Obesity and Altered Aspirin Pharmacology.PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study.Aspirin's effect on platelet inhibition in migraineurs.

P2860

Q22305927-95CCA3F7-17F6-4C3F-A675-3D41B46889D1 Q26851367-0F9C992A-943E-499A-999C-71B6108BE671 Q28200486-744E0A6E-8F2E-4880-A6E6-D862A2BFD326 Q35076036-82FC8CBE-E3CA-4E22-B37D-02427AF46ECE Q36664802-57DD5FD3-B9C1-436E-A223-8B522DC660BD Q36786923-ED936D34-0EB7-4566-B555-5003FCB12720 Q36989841-E0213A02-45AF-4B1D-9D87-7A1A1D6B06E0 Q37378896-F0ECC569-D6D4-403A-9FB9-7B7DD54C4490 Q37919150-9B1119E0-9D46-4B9D-B344-DE0DFD972163 Q37932076-79F4F3D2-2E70-42C7-8E40-0044B64941EE Q38055245-C7803807-4800-4A13-8CE0-64B497EA547B Q38818898-68D1CF91-0450-4855-91C2-576B25D989E8 Q41415961-649BE14E-C783-49AA-A903-2BA1452D7B1F Q42985242-F5D8CF1E-3B22-4AB7-AE65-A876958406F5 Q44277034-642A099E-3E84-4B10-AB77-8FA5DF1E984C Q45888145-BA71775B-5CEA-4B50-8ECC-6334D4158706 Q46373377-05A24257-18C2-4803-9B57-68DE27A010DD Q48302820-4E60E32F-B393-4751-8B7D-EABEABE3CA10 Q50063183-4AF307F8-C9BA-4FED-8A8C-DA0547FE5000 Q51347759-9DB159F8-4E45-49D1-8160-B11DD17D026E

P2860

Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects

http://www.wikidata.org/entity/Q28196731

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Obesity is associated with imp ...... c acid in nondiabetic subjects

@ast

Obesity is associated with imp ...... c acid in nondiabetic subjects

@en

Obesity is associated with imp ...... c acid in nondiabetic subjects

@nl

type

label

Obesity is associated with imp ...... c acid in nondiabetic subjects

@ast

Obesity is associated with imp ...... c acid in nondiabetic subjects

@en

Obesity is associated with imp ...... c acid in nondiabetic subjects

@nl

prefLabel

Obesity is associated with imp ...... c acid in nondiabetic subjects

@ast

Obesity is associated with imp ...... c acid in nondiabetic subjects

@en

Obesity is associated with imp ...... c acid in nondiabetic subjects

@nl

P1433

Q28196731-1B87264B-709A-4D81-86FC-6E2D7EADE36E

P1476

Q28196731-0C972EC3-AAF1-4E25-B9A7-C54BF101D65D

P2093

Q28196731-6D81D6DE-7B22-41A4-B62D-9D241DEFC0A6

Q28196731-A5B841D1-C3E7-4CD4-B758-D2F96F0E605D

Q28196731-CA03FDF8-4E5C-46B0-9E47-EF9046D454AE

Q28196731-D0C5BC05-16D0-472F-B8C3-3701E011C400

P2860

Q28196731-00D4948A-5CBE-497E-A596-4D8F7C15A3C3

Q28196731-0D3ECC26-B772-42DB-92E9-EEA5716BDB76

Q28196731-0DA51205-9498-4286-9EE6-CF54152FD94C

Q28196731-21871BAA-9F5F-4393-A78B-4EC05F126C19

Q28196731-25EB1946-44A0-4138-9F02-663813810F8F

Q28196731-35CF2981-9DE1-49C7-9B27-C665C462B0CA

Q28196731-4457A133-1330-4BFA-8A2E-52F5828AFF26

Q28196731-6893F6C8-2DDA-4468-A44B-8E9B7ED3D1BB

Q28196731-7FAE021A-9D5F-4EEC-B775-EEBDE74B3FBE

Q28196731-7FC1F898-AD33-44C8-B647-962D20A6C893

P2888

Q28196731-A86C16E8-0DF7-4B9B-A16A-BF5CD060D017

P304

Q28196731-4E4CF1A5-1D21-435B-B3BF-F61DE8BA055B

P31

Q28196731-F21BD1A6-97AF-4388-852D-F94061410C12

P356

Q28196731-EE6AE3D7-3774-4806-B98A-5E67EEB32D07

P407

Q28196731-C8239A8D-669D-4C3B-AD4B-61093A186A30

P433

Q28196731-F16E4244-BA26-4C34-8464-F5E832457E17

P478

Q28196731-D37F7D41-65C1-4696-A93E-CB952A735559

P50

Q28196731-D27D6B08-71F3-4C2A-ACF7-9F61B57B5ED8

P577

Q28196731-DE40183B-2B3B-4C61-A835-9C119AB86617

P5875

Q28196731-BDD6D783-DF2A-41B5-839A-25AC6D9849E5

P6179

Q28196731-B0922E55-C99F-47C2-AFBB-A540E38A71BE

P698

Q28196731-16B66DC3-248F-4321-A973-5A480B5CF96A

P921

Q28196731-5A8C8385-F34A-41C5-BEE4-4543038904A3

P356

P1433

International Journal of Obesity

P1476

Obesity is associated with imp ...... c acid in nondiabetic subjects

@en

P2093

J Westerbacka

http://www.w3.org/2001/XMLSchema#string

M Tamminen

http://www.w3.org/2001/XMLSchema#string

R Lassila

http://www.w3.org/2001/XMLSchema#string

S Vehkavaara

http://www.w3.org/2001/XMLSchema#string

P2860

Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Platelet dysfunction in type 2 diabetes.

Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects.

Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease.

Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.

Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate.

Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.

Increase in the cytosolic concentration of calcium in platelets of diabetics type II.

Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.

P2888

P304

907-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.IJO.0802312

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Hannele Yki-Järvinen

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10661680

http://www.w3.org/2001/XMLSchema#string

P6179

1045207667

http://www.w3.org/2001/XMLSchema#string

P698

12861231

http://www.w3.org/2001/XMLSchema#string

P921